TrumpLyftAlles | 2 points
The Safety of Double- And Triple-Drug Community Mass Drug Administration for Lymphatic Filariasis: A Multicenter, Open-Label, Cluster-Randomized Study[-] TrumpLyftAlles | 1 points
Fits a tweet:
Safety study reviewed adverse events (AEs) for 12K subjects who took 2 drugs to kill parasites to 14K who took the 2 drugs + #ivermectin.
Incidence of AEs was the same for the 2 groups, implying IVM did not cause the AEs.
All 6 serious AEs recovered.
This safety study compared the adverse events of ivermectin plus two other drugs, to the two drugs without ivermectin.
11% of 27K participants had mild adverse events (AEs) that did not prevent them from working or going to school. 1% had AEs that interfered with work/school. There were 6 serious AEs. 5 were hospitalized, 4 released the next day, 1 was released after 4 days. Their illnesses may have been related to the treatment. All recovered.
The incidence of AEs for ivermectin+DA was the same as the DA cohort, indicating IVM did NOT contribute to the AEs.
grade 1 AEs were mild and did not prevent the participant from working or going to school. Grade 2 AEs were moderate and interfered with work or school attendance. Participants with AEs with severity of grade 3 or higher that interfered with activities of daily living were referred for evaluation by a physician who was not part of the research team, who documented the nature of the problem and determined whether it required hospitalization or otherwise met criteria for an SAE [14].
12,280 took diethylcarbamazine plus albendazole (DA) and 14556 took ivermectin plus DA (IDA).
Overall, 12.0% of all participants experienced AEs (12% after IDA and 12.1% after DA), and there were no statistically significant differences in overall AE rates or severity of AEs by treatment regimen
11% experienced adverse events (AEs) were grade 1, 1% had grade 2. There were 6 AEs deemed serious. 5 were hospitalized. 4 were discharged the next day, one 4 days later. All recovered after 1
[-] TrumpLyftAlles | 1 points | May 20 2020 06:01:29
June 2019
Large community studies were conducted in five countries between October 2016 and November 2017. Two studies were performed in areas with no prior mass drug administration (MDA) for filariasis (Papua New Guinea and Indonesia), and three studies were performed in areas with persistent LF despite extensive prior MDA (India, Haiti, and Fiji).
IVERTODO Review this. It looks like ivermectin and no-ivermectin had the same low rate of adverse events. CHECK.
permalink